Vice-Chair and Professor of Pathology
Brigham & Women's Hospital and Harvard Medical School
CHRISTOPHER D.M. FLETCHER, M.D., FRCPath, graduated from St. Thomas’s Hospital Medical School in London and obtained postgraduate qualifications from the Royal College of Pathologists (MRCPath - 1988) and the University of London (M.D. - 1991) in the UK. Dr. Fletcher has published extensively on the pathology of soft tissue tumors and is probably best known for his work challenging the diagnostic entities of malignant fibrous histiocytoma and hemangiopericytoma. He described for the first time a variety of lesions, including, among others, deep benign fibrous histiocytoma, angiomyofibroblastoma, retiform hemangioendothelioma, spindle cell liposarcoma, myoepithelial lesions of soft tissue, cellular angiofibroma and soft tissue angiofibroma. He has worked extensively on cytogenetic/molecular genetic/morphologic correlations in soft tissue tumors. He was Chairman of the WHO Working Group on the classification of soft tissue and bone tumours (2002-2017), having been senior editor of both the 2002 and 2013 classifications. He has more than 600 publications, including more than 400 original papers on soft tissue neoplasms, and several books, among which are the two-volume Diagnostic Histopathology of Tumors, the 5th edition of which was published in 2020, and the 3rd series AFIP Fascicle on Soft Tissue Tumors. He has been the recipient of numerous honors and awards, is on the editorial boards of 17 international journals and was President of the Association of Directors of Anatomic and Surgical Pathology for two terms from 2003-2006. He has also been President of the US-Canadian Academy of Pathology (USCAP), President of the International Society of Bone & Soft Tissue Pathology and President of the Arthur Purdy Stout Society. Before moving to the United States in 1995, Dr. Fletcher is currently Professor of Pathology at Harvard Medical School, Vice Chair for Anatomic Pathology at Brigham and Women’s Hospital, Boston, Massachusetts and Chief of Onco-Pathology at the Dana-Farber Cancer Institute in Boston.
